National Bleeding Disorders Foundation/
merzbranding.com
Aug 28, 2026, 16:44
HEMGENIX Supply Update for the Hemophilia B Community – National Bleeding Disorders Foundation
National Bleeding Disorders Foundation shared on LinkedIn:
”Treatment availability update for the hemophilia B community:
CSL Behring has shared an update regarding the availability of HEMGENIX (etranacogene dezaparvovec-drlb), its gene therapy for hemophilia B.
Following the temporary global stockout announced in March 2026, the company reports that it reestablished a limited supply in April and continues to actively manage existing supply.
Read the full update and learn more.”
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 11:24Brandon Daniel D’Costa: Building Stronger Stakeholder Relationships Through Empathy and Open Communication
-
Oct 13, 2026, 11:08Renel Tique: 5th International Conference on Hemophilia and Rare Bleeding Disorders
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF